Growth & Failure cover image

Dr. Aoife Brennan, President & CEO of Synlogic Therapeutics

Growth & Failure

CHAPTER

Rare Disease Innovation Unit at Biogin

The former head of rare disease innovation at biogin is now president in co of sin logic. What encouraged him to leave the company and join sonagi? And if you could describe what sinlogic is happy to so bi thall end the time, i probably would have stayed at bigen If they had continued to pursuit te rare disease focus strategy.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner